The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma

Overview

Journal J Hepatocell Carcinoma

Date 2020 Feb 28

PMID 32104669

Citations 52

Authors

Prabhsimranjot Singh

Sudhamshi Toom

Akshay Avula

Vivek Kumar

Osama E Rahma

Affiliations

Soon will be listed here.

Abstract

Locoregional therapies (LRTs) including radiofrequency ablation, surgical resection, and TACE, play a pivotal role in the treatment of early stage/locally advanced hepatocellular carcinoma (HCC). Besides their direct effect on tumor cells, LRTs also play an essential role in the immunomodulation of the tumor microenvironment which is of interest in the current era of cancer immunotherapy. In this review, we describe the HCC immune microenvironment and how it is affected by LRTs as described in multiple pre-clinical and clinical studies and provide the rationale for combining LRTs with immunotherapy.

Citing Articles

Real world study on combining local interventions with systemic therapy in unresectable hepatocellular carcinoma.

Xue Z, Yao M, Chen K, Huang T, Li J, Chen J Sci Rep. 2025; 15(1):4188.

PMID: 39905151 PMC: 11794854. DOI: 10.1038/s41598-025-88813-8.

Efficacy of Adding Locoregional Therapy in ATZ/BEV-Treated Patients with Stable HCC.

Hosui A, Hayata N, Kurahashi T, Namiki A, Okamoto A, Aochi K Cancers (Basel). 2025; 17(2.

PMID: 39857967 PMC: 11763424. DOI: 10.3390/cancers17020185.

T-cell Receptor Repertoire Analysis in the Context of Transarterial Chemoembolization Synergy with Systemic Therapy for Hepatocellular Carcinoma.

Li J, Zhang Y, Hu L, Ye H, Yan X, Li X J Clin Transl Hepatol. 2025; 13(1):69-83.

PMID: 39801788 PMC: 11712086. DOI: 10.14218/JCTH.2024.00238.

miR-328-3p suppresses hepatocellular carcinoma progression by regulating HMOX1 expression.

Wang W, Li J, Pan C, Wang D, Dong J Discov Oncol. 2024; 15(1):735.

PMID: 39617834 PMC: 11609136. DOI: 10.1007/s12672-024-01610-z.

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study.

Meng L, Li H, Ji Y, Yu P, Wang Z, Cao L Cancer Immunol Immunother. 2024; 74(1):13.

PMID: 39499356 PMC: 11538227. DOI: 10.1007/s00262-024-03857-5.

References

Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu M, Allen C . The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017; 3(12):1683-1691. PMC: 5824275. DOI: 10.1001/jamaoncol.2017.3055. View

Zhu A, Kang Y, Yen C, Finn R, Galle P, Llovet J . Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(2):282-296. DOI: 10.1016/S1470-2045(18)30937-9. View

El-Khoueiry A, Sangro B, Yau T, Crocenzi T, Kudo M, Hsu C . Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; 389(10088):2492-2502. PMC: 7539326. DOI: 10.1016/S0140-6736(17)31046-2. View

Zhu A, Finn R, Edeline J, Cattan S, Ogasawara S, Palmer D . Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; 19(7):940-952. DOI: 10.1016/S1470-2045(18)30351-6. View

Ringelhan M, Pfister D, OConnor T, Pikarsky E, Heikenwalder M . The immunology of hepatocellular carcinoma. Nat Immunol. 2018; 19(3):222-232. DOI: 10.1038/s41590-018-0044-z. View

Liu G, Ouyang Q, Xia F, Fan G, Yu J, Zhang C . Alpha-fetoprotein response following transarterial chemoembolization indicates improved survival for intermediate-stage hepatocellular carcinoma. HPB (Oxford). 2018; 21(1):107-113. DOI: 10.1016/j.hpb.2018.06.1800. View

Pardee A, Shi J, Butterfield L . Tumor-derived α-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells. J Immunol. 2014; 193(11):5723-32. PMC: 4239186. DOI: 10.4049/jimmunol.1400725. View

Bruix J, Qin S, Merle P, Granito A, Huang Y, Bodoky G . Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2016; 389(10064):56-66. DOI: 10.1016/S0140-6736(16)32453-9. View

Goossens N, Sun X, Hoshida Y . Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol. 2015; 2(4):371-379. PMC: 4662420. DOI: 10.2217/hep.15.26. View

10.

Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G . Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell. 2015; 28(6):690-714. DOI: 10.1016/j.ccell.2015.10.012. View

11.

Sangro B, Gomez-Martin C, Mata M, Inarrairaegui M, Garralda E, Barrera P . A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013; 59(1):81-8. DOI: 10.1016/j.jhep.2013.02.022. View

12.

Hoechst B, Ormandy L, Ballmaier M, Lehner F, Kruger C, Manns M . A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008; 135(1):234-43. DOI: 10.1053/j.gastro.2008.03.020. View

13.

Wang X, Wang Q . Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity. Can J Gastroenterol Hepatol. 2018; 2018:9049252. PMC: 5899840. DOI: 10.1155/2018/9049252. View

14.

Cui J, Wang N, Zhao H, Jin H, Wang G, Niu C . Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer. 2013; 134(2):342-51. DOI: 10.1002/ijc.28372. View

15.

Medina-Echeverz J, Eggert T, Han M, Greten T . Hepatic myeloid-derived suppressor cells in cancer. Cancer Immunol Immunother. 2015; 64(8):931-40. PMC: 6309820. DOI: 10.1007/s00262-015-1736-y. View

16.

Dromi S, Walsh M, Herby S, Traughber B, Xie J, Sharma K . Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology. 2009; 251(1):58-66. PMC: 2663580. DOI: 10.1148/radiol.2511072175. View

17.

Knolle P, Schlaak J, Uhrig A, Kempf P, Meyer zum Buschenfelde K, Gerken G . Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J Hepatol. 1995; 22(2):226-9. DOI: 10.1016/0168-8278(95)80433-1. View

18.

Duffy A, Ulahannan S, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D . Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2016; 66(3):545-551. PMC: 5316490. DOI: 10.1016/j.jhep.2016.10.029. View

19.

Ilkovitch D, Lopez D . The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res. 2009; 69(13):5514-21. PMC: 2706931. DOI: 10.1158/0008-5472.CAN-08-4625. View

20.

Jenne C, Kubes P . Immune surveillance by the liver. Nat Immunol. 2013; 14(10):996-1006. DOI: 10.1038/ni.2691. View